Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.250
-0.230-4.20%
Volume:72.16M
Turnover:381.46M
Market Cap:98.09B
PE:34.60
High:5.480
Open:5.480
Low:5.235
Close:5.480
52wk High:8.647
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.82
T/O Rate:0.39%
Dividend:0.12
Dividend Rate:2.29%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.58
PE(LYR):34.60
PS:2.49

Loading ...

SBP Group Surges Over 4% in Morning Trade on FDA Clearance for TQB6426

Deep News
·
Sep 03

Movement Alert|SBP GROUP Rises 3.33% in Regular Trading, Core ADC Drug TQB2102 Phase III Trial Hits Primary Endpoint

Market Focus
·
Sep 03

Sino Biopharm Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation

Reuters
·
Sep 01

SBP Group Reports No Share Changes in August; 14.60 Million Shares Earmarked for Future M&A Payout

Bulletin Express
·
Sep 01

Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug

MT Newswires Live
·
Aug 31

SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC

Stock News
·
Aug 31

Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million

Reuters
·
Aug 31

Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets

THOMSON REUTERS
·
Aug 31

Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties

THOMSON REUTERS
·
Aug 31

Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate

Reuters
·
Aug 31

Sino Biopharmaceutical Stock Sheds 2.6% in Hong Kong

Dow Jones
·
Aug 31

Movement Alert|SBP GROUP Falls 3.04% in Regular Trading, Trading at HK$5.425

Market Focus
·
Aug 31

SBP Group Unveils Phase I Data: Single-Dose Kylo-11 Achieves Up to 97% Sustained Lp(a) Reduction

Bulletin Express
·
Aug 31

SBP Group Secures NMPA and FDA Green Lights for LM-364 “Nectin-4TME ADC” Clinical Trials

Bulletin Express
·
Aug 28

Sino Biopharm Wins NMPA Nod to Start LM-364 Nectin-4 TME ADC Trial in Solid Tumors

Reuters
·
Aug 28

Sino Biopharmaceutical - Lm-364 'Nectin-4Tme ADC' Receives Nmpa Clinical Trial Approval for Advanced Solid Tumors

THOMSON REUTERS
·
Aug 28

Movement Alert|SBP GROUP Falls 3.05% in Regular Trading, Trading at HK$5.545

Market Focus
·
Aug 27

China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval

Deep News
·
Aug 26

Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 26

Movement Alert|SBP GROUP Rises 3.29% in Regular Trading, GLP-1 Weight Management Microneedle Patch Receives US FDA Clinical Trial Approval

Market Focus
·
Aug 26